The American College of Toxicology (ACT) is a global community of scientists from all aspects of toxicology, aiming to facilitate the exchange of information and perspectives on safety assessment and applied toxicology.

The ACT offers a platform for toxicologists to connect, learn, and network in a friendly environment.  The 44th Annual Meeting, which will feature a diverse scientific program, educational courses, distinguished speakers, a poster session, and networking events, takes place later this month in Orlando.

Our scientific highlights…

We can’t wait to hear the presentations within the Monday afternoon session: In Silico Models: When and How Will We Be Animal Free?  We know that aspects of safety assessment will increasingly move towards in silico models when robust and reliable information can be used in a regulatory setting and we’re excited to hear about some of the current “hot topics” in this area; niche solutions helping pharmaceutical developers chose compounds for development and assist in safety assessment. The goal of this session is to update delegates on the latest emerging in silico techniques that soon may become standard safety assessment tools.  We will be there!

During Tuesday, we’ll be catching up with all things nitrosamines at Managing Nitrosamine Impurities in Pharmaceuticals: 2023 Update.  A great selection of speakers – from industry, government and private companies, will be examining factors that affect N-nitrosamine creation and potency, potential alternative routes to exclude N-nitrosamine formations as well as regulatory approaches to N-nitrosamine assessments. Over the last 4 years, nitrosamines have come under intense scrutiny from both regulatory authorities and the pharmaceutical industry. In this fast-paced area of science, we’re looking forward to learning about the scientifically-valid and regulatory-acceptable solutions being identified.   Also, our very own Kevin Cross will be speaking about predicting N-nitrosamine potency for Acceptable Intake (AI) limits – it is not to be missed.

On Wednesday, the Practices and Perspectives in Secondary Pharmacology looks interesting and this topic has a wealth of relevance to our on-going R&D at Instem.  Secondary Pharmacology is one of the six Weight of Evidence factors within the S1B addendum (supported by our new Advance service).  This session will focus on cross-study comparisons using SEND data which are expected to improve the identification of unique findings related to the intended target, species or duration of dosing.  The SEND standard is something Instem has always been passionate about supporting, understanding and using effectively.  We’re excited to join this session (and more) at the ACT.

Connect with us:

Exhibitor Hosted Talking Tox Session: Using Translational Science Tools to Support an Integrated Weight of Evidence Approach: Case Study on ICH S1B Carcinogenicity Assessment. Tuesday, November 14, 12:00 PM – 12:55 PM (EST), Room E5.

We will present the latest intelligence surrounding translational safety assessment, including an illustration of the recently revised ICH S1B guideline. A demonstration of how clinical and preclinical data, together with evidence from literature and database searches, can be collated and reviewed in a defined workflow, then extrapolated to gain scientific insight.

Symposium Gold Sponsor of ACT Session number S15, Managing Nitrosamine Impurities in Pharmaceuticals: 2023 Update Wednesday, November 15, 9 AM – 12.00 PM (EST)

Symposium Presentation: Factors Influencing the Potency of N-Nitrosamines: Reviewing the Carcinogenic Potency Categorization Approach Presented by: Kevin Cross, PhD, VP of Regulatory Science.

Poster time!

We have posters at ACT and we’d love to walk you through them.  We will be found at our posters on Monday, November 13, 5.00 PM – 6.30 PM (EST).  E-copies are also available upon request.

  • Translational and in silico assessment of liver injury for 4-hydroxy-2,6-dichlorodiphenylamine. Presenting Author: Brenda Finney, PhD, Vice President, In Silico & Translational Science, Instem
  • Standardized Target Carcinogenicity Assessment (TCA) Enables ICH S1B-based Regulatory Decisions Presenting Author: Frances Hall, PhD, Senior Director, In Silico Solutions, Instem

Not going to be at ACT? No worries!
We’ll be sharing the content virtually and happy to meet with you online. Contact me or one of the Instem team, via to continue the conversation.

Author: Frances Hall PhD, Senior Director for In Silico & Translational Science Solutions at Instem